CompletedNCT02013609
Brexpiprazole Added to Antidepressants for Depression in Working or Studying Adults
About this title
Read the official source — NCT02013609Medication studyAges 18–35United States
Understand this study
Who was this study for?
Listed age limits: 18 years to 35 years.
- Listed locations
- Cerritos and 23 more locationsSee all locations and recruitment
- Study phase
- Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
Study information
Study start dateNovember 2013
- Recruitment status
- Completed
- Enrollment listed in the registry
- 48
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
- Sponsor type
- Pharmaceutical company
- Study type
- Drug
- Intervention type
- Drug
- Study phase
- Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
- Locations
- United States
- Age range
- From 18 Years to 35 Years
- Official registry ID
- NCT02013609
- Official title
Show the full official title
Protocol 331-13-003: An Exploratory, Multicenter, Open-label, Flexible-dose Trial of Brexpiprazole (OPC 34712) as an Adjunctive Treatment in Active Adults, 18 to 35 Years Old, With Major Depressive Disorder Who Are in a School or Work Environment.
Looking for a study you can join?
Explore recruiting studiesRecruitment & locations
CompletedThis badge reflects the study status reported by the registry. Check the registry for the latest information.
Cerritos · Costa Mesa · Garden Grove
21 more locations
- Glendale
- Orange
- Riverside
- San Diego
- Norwich
- Fort Myers
- Hialeah
- Melbourne
- Orlando
- Atlanta
- Prairie Village
- Weymouth
- Las Vegas
- Brooklyn
- Jamaica
- Staten Island
- Portland
- Austin
- Houston
- San Antonio
- Seattle
Interested in joining this study?
Questions about this study
Who is behind this study?
The study sponsor is Otsuka Pharmaceutical Development & Commercialization, Inc., a pharmaceutical company.
Did this study involve medication?
Yes. The study involved medication, including Brexpiprazole.
Who was this study for?
Listed age limits: 18 years to 35 years.
